Related Experiment Video
Updated: Jun 8, 2026
10:44
A Plate-based Cytotoxicity Assay for the Assessment of Rat Placental Natural Killer Cell Cytolytic Function
Published on: June 2, 2019
Pregnancy decreases rat CYP1A2 activity and expression
Alysa A Walker1, Leslie Dickmann, Nina Isoherranen
1Department of Pharmaceutics, University of Washington, Seattle, Washington 98195-7610, USA.
Summary
Pregnancy reduces the activity of CYP1A2 enzymes, impacting drug metabolism. This study in rats shows decreased CYP1A2 protein and mRNA expression during gestation, suggesting a model for human pregnancy effects.
Area of Science:
- Pharmacology
- Drug Metabolism
- Biochemistry
Background:
- Pregnancy alters drug metabolism, increasing clearance via CYP3A and CYP2D6 enzymes.
- Conversely, pregnancy is associated with reduced clearance of drugs metabolized by CYP1A2.
Purpose of the Study:
- To investigate if decreased CYP1A2 activity during human pregnancy is due to reduced CYP1A2 protein and mRNA expression.
- To explore potential mechanisms behind these pregnancy-induced changes in CYP1A2 activity and expression using a rat model.
Main Methods:
- Measured hepatic CYP1A2 activity, protein, and mRNA in pregnant and non-pregnant rats.
- Assessed the impact of estradiol and progesterone on CYP1A2 mRNA in rat hepatocytes.
- Tested the in vitro effect of estrogens or progesterone on CYP1A2 activity.
Main Results:
- CYP1A2-mediated probe drug clearance decreased by 48-62% during pregnancy.
- A significant reduction in CYP1A2 protein expression was observed during mid- and late-gestation.
- CYP1A2 mRNA levels decreased significantly only in late pregnancy; estradiol and progesterone had no effect.
Conclusions:
- Pregnancy leads to decreased CYP1A2 activity and protein expression, with a modest decrease in mRNA.
- The rat serves as a viable model for studying pregnancy-induced alterations in CYP1A2 activity relevant to humans.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...